Meta-analysis of independent, real-world studies was presented at ENDO 2022 and shows even better Afirma GSC performance compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a
First randomized, clinical study demonstrating prognostic value of Decipher Prostate test in postoperative salvage setting without hormone therapy SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data reinforcing the
Findings from Phase II AtezoTRIBE trial published online in The Lancet Oncology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company’s Immunoscore Immune Checkpoint
- First findings from study analyzing outcomes of more than 10,000 men in national SEER database who underwent Decipher testing - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC)
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in two upcoming investor conferences.
Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their
Decipher Prostate test specifically cited for its extensive clinical evidence, including from multiple phase 3 randomized trials in high-risk prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that an updated clinical
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
